Читать книгу Magnetic Nanoparticles in Human Health and Medicine - Группа авторов - Страница 3

1 Chapter 1Table 1.1 Magnetic susceptibility values for different bulk magnetic materi...

2 Chapter 2Table 2.1 Examples of the MNPs clinically approved or in the phase of clini...

3 Chapter 4Table 4.1 An overview of various biomaterials for tissue engineering applic...

4 Chapter 8Table 8.1 SPIONs theranostics contributions.

5 Chapter 9Table 9.1 Characteristics of preclinical imaging techniques with biomedical ...Table 9.2 Physicochemical characteristics of SPECT and PET emitters.Table 9.3 Most commonly used SPECT/PET emitters for Nuclear/MR or multimodal...

6 Chapter 10Table 10.1 Magnetic nanoparticles with potential use in hyperthermia and rel...Table 10.2 Synthesis methods of magnetic nanoparticles and alloys.

7 Chapter 11Table 11.1 Summary of important applications of MNP in drug delivery and mag...Table 11.2 Biopharmaceutical classification system (BCS).

8 Chapter 12Table 12.1 Reduction in RFAMF‐induced heating efficiency with increasing med...Table 12.2 Essential magneto‐structural properties of the phosphate and TMAO...

9 Chapter 13Table 13.1 Magnetization and magnetic behavior of nanoparticles according to...Table 13.2 Classification of the lipid‐based liposome‐like vesicles and thei...Table 13.3 Classification of nonlipid‐based liposome‐like vesicles and their...Table 13.4 Benefits and limitations in cyclodextrin use as pharmaceutical in...

10 Chapter 15Table 15.1 Standard parameters used for the simulation of SLP values for LR...Table 15.2 Comparison of SLP dependencies from theories (LRT and SWMBT) and...

11 Chapter 16Table 16.1 Summary ofin vitro studies performed in recent years highlightin...Table 16.2In vivo toxicity results of SPIONs.Table 16.3 Some of the commercialized SPIONs which are used for different d...Table 16.4 Cytotoxicity of Fe₃O₄ nanoparticles in different cell lines.Table 16.5 Representative magnetic nanoparticles for magnetic nanoparticle‐...Table 16.6 The distribution of MNPs in organs and tissues, depending on the...

12 Chapter 17Table 17.1 Size and shape control of the most reported synthesis methods of...Table 17.2 Some published values are reported in size, composition, and sha...

13 Chapter 18Table 18.1 Summary of clinical trials on MHT using magnetic nanoparticles.Table 18.2 Nanoparticle constructs utilized for magnetic hyperthermia thera...Table 18.3 Summary of recent studies on magnetic fluid hyperthermia therapy...